Build consensus and foster knowledge sharing to enable the identification of suitable biomarkers or biosignatures for TB point-of-care tests

NDWG priority addressed

To reduce the current gap of 3.6 million TB cases missed each year and improve TB case detection through the development and use of accurate tests that are suitable for use in a patient-centered fashion at all levels of the healthcare system, including at the point of care.

Required tests:
Tests that can be used at all levels of the healthcare system, including at the point of care, for all populations, including children and those living with HIV, in particular a non-sputum-based biomarker test for diagnosis and a triage/rule-out test.

Background

Recently, the World Health Organization (WHO) published high-priority Target Product Profiles (TPPs) for TB diagnostics. A non-sputum-based biomarker test for diagnosis and a triage/rule-out test were rated highest by all stakeholder groups. However, despite decades of research and significant investments to identify TB biomarkers, leading to a large number of studies and publications, no diagnostic test with sufficient performance is imminent, and the search for predictive (non-DNA) biomarkers remains a priority. The lack of a good understanding of the current landscape for TB biomarkers and the absence of a consensus-based biomarker scoring system to identify and prioritize biomarkers with translational potential stifle test development.

Goal and Objectives

Build consensus and foster knowledge sharing to enable the identification of suitable biomarkers or biosignatures for TB point-of-care tests through:

  • Development of a consensus-based biomarker scoring system to assess the status of a biomarker in relation to the intended diagnostic use-case.
  • Performing a comprehensive and systematic review of relevant biomarkers to point of care tests for the detection of active TB (see TPPs mentioned above).
Work plan highlights and main activities
  • Establish a Task Force of experts in the field contributing in an advisory capacity to the development of a TB Biomarker Scoring System, with a focus on the assessment of priorities.
  • Ensure regular consultations of experts in the task force and organize a consensus-building meeting to be held in Liverpool on 27 October.
  • Publish the outcome as a peer-reviewed publication which will be co-authored by experts in the task force.

 

Coordinator

Tobias Broger, FIND

 

Task Force members

  • Daniela Cirillo, San Raffaele Scientific Institute, Italy (NDWG Co-Chair)
  • Claudia Denkinger, FIND, Switzerland
  • Mark Doherty, SSI
  • Jennifer Gardiner, BMGF, USA
  • Marila Gennaro, Rutgers, USA
  • Simone Joosten, Leiden University, The Netherlands
  • Emily MacLean, McGill
  • Payam Nahid, UCSF, USA
  • Madhu Pai, McGill, Canada
  • Marco Schito, C-PATH, USA
  • Tom Scriba, University of Cape Town, South Africa
  • Robert Wallis, Aurum Institute, South Africa
  • Gerhard Walzl, Stellenbosch University, South Africa
  • Seda Yerlikaya, FIND
  • Alimuddin Zumla, UCL, UK